“…◾ Patients with type 2 diabetes mellitus (T2DM) have an elevated risk of heart failure (HF), which may be caused by macrovascular disease, microvascular disease, volume overload, impaired kidney function, and/or direct adverse effects of diabetes on the myocardium [1][2][3][4][5][6] ◾ Sodium glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of HF events in large scale trials [7][8][9][10][11] ; however, the mechanism of protection is unknown, and it is not known whether these benefits extend to patients with reduced and preserved ejection fraction (EF)…”